+Vote!
PR News Wire (Free subscription) | 05/15/2008
ROCKVILLE, Md., May 15 /PRNewswire-FirstCall/ -- Human Genome Sciences,
Inc. (Nasdaq: ) today announced that Kevin P. McRaith has joined the
Company as Vice President, Hepatology Franchise. Mr. McRaith, formerly Vice
President, Sales & Marketing - Hematology, Genentech Corporation, will
report to Barry A. Labinger, Executive Vice President and Chief Commercial
Officer.
(Logo: )
"Kevin McRaith...
+Vote!
Red Orbit (Free subscription) | 05/08/2008
ROCKVILLE, Md., May 8 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced that John L. LaMattina, Ph.D., who retired in late 2007 as President of Pfizer Global Research and Development, has been appointed to the HGS Board of Directors.
+Vote!
The Street (Free subscription) | 05/06/2008
Obagi Medical Products and Human Genome Sciences both fall on earnings misses.
+Vote!
Seeking Alpha (Free subscription) | 05/06/2008
Human Genome Sciences Inc. (HGSI) Q1 2008 Earnings Call Complete Story »
+Vote!
Red Orbit (Free subscription) | 05/06/2008
ROCKVILLE, Md., May 5 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced financial results and key developments for the quarter ended March 31, 2008.
+Vote!
The Washington Business Journal (Free subscription) | 05/05/2008
Human Genome Sciences Inc., which is developing drugs for lupus, hepatitis and liver cancer, reported a smaller loss for its latest quarter as it collects payments from its drug development partners. (HGSI)
+Vote!
The Washington Times (Free subscription) | 04/29/2008
Human Genome Sciences shares are down about 28 percent in the past six months, but investors and...
+Vote!
PR News Wire (Free subscription) | 04/28/2008
... and great medicine to
bring innovative drugs to patients with unmet medical needs.
HGS and Human Genome Sciences are trademarks of Human Genome Sciences,
Inc.
Safe Harbor Statement
This announcement contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended....
1Vote!
Medical News Today (Free subscription) | 04/23/2008
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that it has completed enrollment and initial dosing in BLISS-52, one of two pivotal Phase 3 clinical trials of LymphoStat-B(R) (belimumab) in patients with active systemic lupus erythematosus (SLE).
+Vote!
Life Science World (Free subscription) | 04/22/2008
[NEWS] - Completion of enrollment in second Phase 3 trial expected by end of summer - - First Phase 3 data now expected by mid-2009, with all Phase 3 data expected in fall 2009 - ROCKVILLE, Md., April 22 /PRNewswire-FirstCall/ — Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has completed enrollment and initial dosing in BLISS-52, one of two pivotal Phase 3 clinical trials...
+Vote!
Red Orbit (Free subscription) | 04/17/2008
ROCKVILLE, Md., April 16 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.
+Vote!
Market Wire - Investment Opinion (Free subscription) | 03/25/2008
MIAMI, FL (MARKET WIRE) Wall Street Press Wire (www.WallStreetPressWire.com) is pleased to highlight its "stocks on the move" for Tuesday. Our list includes: Universal Detection Technology (OTCBB: UDTT), CIT Group Inc. (NYSE: CIT), Human Genome Sciences, Inc. (NASDAQ: HGSI) and SIRIUS Satellite Radio (NASDAQ: SIRI).
+Vote!
PR News Wire (Free subscription) | 03/14/2008
ROCKVILLE, Md., March 14 /PRNewswire-FirstCall/ -- Human Genome
Sciences, Inc. (Nasdaq: ) announced today that its presentation at the
Cowen and Company 28th Annual Health Care Conference will be webcast and
may be accessed at .
(Logo: )
A member of Human Genome Sciences' senior management team will present
a corporate overview on Wednesday, March 19, 2008 from 8:45 to 9:20 am
Eastern Time.
...
+Vote!
Sound Money Tips (Free subscription) | 03/05/2008
Human Genome Sciences, Inc. (HGSI)Q4 2007 Earnings Call February 25, 2008 4:30 pm ETExecutivesH. Thomas Watkins - President and Chief Executive OfficerTimothy C. Barabe - Senior Vice President and Chief Financial OfficerDavid C. Stump, M.D. - Executive Vice President, Research and DevelopmentJames H. Davis, Ph.D., J.D. - Executive Vice President and General Counsel AnalystsAnalyst for Yaron Werber...
+Vote!
PR News Wire (Free subscription) | 03/03/2008
ROCKVILLE, Md., March 3 /PRNewswire-FirstCall/ -- Human Genome
Sciences, Inc. (Nasdaq: ) announced today that a panel presentation and
discussion at the Susquehanna Financial Group Second Annual SIGnificant
Investment Options in Healthcare Conference will be webcast and may be
accessed at .
(Logo: )
A senior member of Human Genome Sciences' clinical management team will
participate in a...
